TiCARos’ mission is to create a paradigm shift in the CAR-T therapeutics landscape that could achieve a complete cure for both intractable hematologic malignancies and advanced solid tumors ...
Among the 13 CAR-T therapeutics that have received regulatory approval are Gilead’s Yescarta and Immuneel Therapeutics’ ...
The CAR-T landscape has quickly transformed from a pioneering breakthrough to a highly competitive and evolving market. Ben Hargreaves finds that the early leaders, Gilead and Novartis ...
What challenges does Allogene face in the competitive CAR T landscape? Allogene operates in a highly competitive field, with several companies developing both autologous and allogeneic CAR T ...
The gist of this is that the technology, if deployed with clinical success, would disrupt the CAR-T landscape. I will be going over several reasons why below, but the promise of this is another ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback